{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-127004","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.088095+00:00","generated_at":"2026-05-30T00:29:53.152285+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cue Biopharma Q3 net loss narrows to $8.7M; CUE-101 combo shows 46% ORR in HPV+ HNSCC","bullets":["Net loss of $8.7M ($0.17 per share) vs $11.0M loss ($0.24) in Q3 2023; collaboration revenue rose to $3.3M.","Cash $32.4M, expected to fund operations into Q4 2025; $12M public offering priced in quarter.","CUE-101 + KEYTRUDA Phase 1 data: 46% ORR, 91.3% 12-month OS, 21.8-month mOS in 1L HPV+ HNSCC.","CUE-102 monotherapy: 67% DCR in late-stage pancreatic cancer; favorable tolerability with no DLTs.","Appointed Lucinda Warren as Chief Business Officer; preclinical autoimmune programs advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-127004","json":"https://secwatch.observer/filing/0000950170-24-127004.json","markdown":"https://secwatch.observer/filing/0000950170-24-127004.md","text":"https://secwatch.observer/filing/0000950170-24-127004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024127004/0000950170-24-127004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024127004/cue-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:29:53.152285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}